- Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial.
- Since that time, Savara has met with the FDA and has designed a new Phase 3 trial, IMPALA 2, that capitalizes on the strong points of Molgradex in IMPALA.
- I'm optimistic about Molgradex approval and mildly bullish on Savara from here, but I don't personally think the risk/reward is compelling enough to start a position.
For further details see:
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex